Clinical Trials

18 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05275439 2026-03-18

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Phase 1 Terminated

106 enrolled 28 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06514261 2026-03-18

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

45 enrolled

Leukemia, Myeloid, Acute

NCT04227847 2026-03-16

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT06763341 2026-03-13

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

12 enrolled

Leukemia, Myeloid, Acute

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

30 enrolled

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05453903 2026-03-12

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Leukemia, Myeloid, Acute

NCT05834244 2026-03-11

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

32 enrolled

Leukemia, Myeloid, Acute

NCT06498973 2026-03-05

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

43 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06177067 2026-03-04

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

24 enrolled

Phase 1 Not yet recruiting

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07439211 2026-03-03

GAVEL

48 enrolled

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04964505 2026-02-23

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Phase 1 Terminated

16 enrolled

Phase 1 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07177079 2026-02-23

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

30 enrolled

Leukemia, Myeloid, Acute

NCT06616636 2026-02-18

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

24 enrolled

Phase 1 Not yet recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03628209 2026-02-05

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

21 enrolled

Sarcoma

Sarcoma, Osteosarcoma

NCT06372717 2026-02-04

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Classical hematologyOther hematologic neoplasm

100 enrolled

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1 Completed

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04139434 2026-01-23

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Phase 1 Completed

32 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

38 enrolled

Leukemia, Myeloid, Acute

NCT05209295 2026-01-12

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Phase 1 Terminated

2 enrolled

Neoplasms, Hepatic Insufficiency

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Phase 1 Withdrawn

CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT07320235 2026-01-06

IMAGINE

36 enrolled

Leukemia, Myeloid, Acute

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT03613532 2025-12-24

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

102 enrolled